查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032420

癌症疫苗市場報告：按類型、技術、適應症、最終用戶和地區分類（2026-2034 年）

Cancer Vaccines Market Report by Type,, Technology, Indication, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2025年全球癌症疫苗市場規模達83億美元。展望未來，IMARC Group預測，2026年至2034年該市場將以9.62%的複合年成長率成長，到2034年達到194億美元。推動市場成長的主要因素包括癌症發病率上升、免疫療法的進步、政府舉措和資金投入、公眾意識提升和教育宣傳活動的加強、技術的快速發展、戰略聯盟和夥伴關係以及醫療保健支出的成長。

癌症疫苗是一種免疫療法，旨在刺激人體免疫系統識別並攻擊癌細胞。這些疫苗透過訓練免疫系統辨識特定的癌症相關抗原（存在於癌細胞上並能觸發免疫反應的物質）來發揮作用。透過將這些抗原引入體內，癌症疫苗旨在激活免疫系統對抗癌症的天然防禦機制。癌症疫苗主要分為兩類：預防性疫苗和治療性疫苗。預防性癌症疫苗用於預防人類乳突病毒 (HPV) 和乙型肝炎病毒 (HBV) 等傳染性病原體引起的某些癌症。這些疫苗刺激免疫系統觸發針對傳染性病原體的免疫反應，從而降低相關癌症的風險。另一方面，治療性癌症疫苗旨在治療已存在的癌症。它們透過引入癌症特異性抗原或增強免疫系統對這些抗原的識別來發揮作用，從而增強針對癌細胞的免疫反應。這些疫苗還可以進行個人化客製化，靶向個別患者癌細胞中存在的特定抗原。

全球癌症發生率的上升是癌症疫苗市場的主要驅動力。由於癌症是主要死因之一，人們對有效的預防和治療性介入的需求日益成長。此外，包括癌症疫苗在內的免疫療法正成為腫瘤治療領域極具前景的治療方法。新型免疫療法策略的開發以及現有免疫療法的成功應用，都在推動癌症疫苗的需求成長。同時，大眾對癌症預防和早期檢測重要性的認知也不斷提高。宣傳宣傳活動、篩檢計畫和公眾教育活動的增加，正在推動包括癌症疫苗在內的預防措施的需求。此外，製藥公司、研究機構和學術機構之間的合作也在市場上蓬勃發展。這些夥伴關係促進了知識、資源和專業技能的交流，加速了癌症疫苗的研發和商業化。同時，醫療保健支出的成長，尤其是在新興經濟體，正在提高癌症疫苗的可近性和可負擔性。可支配收入的增加、醫療基礎設施的改善以及保險覆蓋範圍的擴大，都為市場成長做出了貢獻。此外，世界各國政府都在積極投資癌症研究和開發，包括疫苗研發，這提振了市場前景。

癌症疫苗市場的發展趨勢與促進因素：

免疫療法的進展

免疫療法利用人體免疫系統的力量靶向並摧毀癌細胞，徹底改變了癌症治療。包括查核點抑制劑和過繼性細胞療法在內的免疫療法取得了成功，為癌症疫苗的研發和應用奠定了堅實的基礎。癌症疫苗能夠誘發針對腫瘤抗原的特異性免疫反應，這進一步完善了現有的免疫療法策略。這種協同作用推動了癌症疫苗作為聯合治療重要組成部分的需求，從而促進了市場成長。

政府措施和資金

世界各國政府都認知到應對日益嚴重的癌症負擔的緊迫性。因此，他們正積極投資於癌症研究與發展以及醫療基礎建設。各國政府為從事癌症疫苗研發的企業提供財政支持、津貼和獎勵措施。此外，監管機構正與疫苗研發企業密切合作，簡化核准流程，促進疫苗進入市場。這些支持政策和資金投入顯著促進了市場成長，並使企業能夠投資於研發、臨床試驗和生產能力建設。

提高公眾意識和宣傳活動

大眾對癌症預防和早期檢測意識的提高顯著影響了癌症疫苗的需求。公共衛生宣傳活動、教育計畫和倡導工作強調了接種疫苗作為預防某些癌症措施的重要性。預防癌症相關感染疾病的疫苗，例如人類乳突病毒(HPV)疫苗和HBV疫苗的成功，進一步鞏固了癌症疫苗的重要性。隨著人們對癌症預防和疫苗接種益處的認知不斷加深，預計癌症疫苗的需求將會增加，從而推動市場成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球癌症疫苗市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 癌症預防疫苗
  • 用於治療的癌症疫苗

第7章 市場區隔：依技術分類

  • 樹突狀細胞癌疫苗
  • 重組癌症疫苗
  • 抗原/佐劑癌症疫苗
  • 病毒載體和DNA癌症疫苗
  • 全細胞癌症疫苗

第8章 市場區隔：依適應症分類

  • 子宮頸癌
  • 攝護腺癌
  • 其他

第9章 市場區隔：依最終用戶分類

  • 兒童
  • 成人

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Anixa Biosciences Inc.
    • Dendreon Pharmaceuticals LLC
    • Dynavax Technologies Corporation
    • GSK plc
    • Merck & Co. Inc.
    • Moderna Inc.
    • OSE Immunotherapeutics
    • Providence Therapeutics
    • Sanofi SA
    • UbiVac Inc.
    • Vaccitech plc
Product Code: SR112026A5901

The global cancer vaccines market size reached USD 8.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 19.4 Billion by 2034, exhibiting a growth rate (CAGR) of 9.62% during 2026-2034. The increasing cancer incidence, advancements in immunotherapy, government initiatives and funding, growing awareness and education, rapid technological advancements, strategic collaborations and partnerships, and increasing healthcare expenditure are some of the major factors propelling the market.

Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. These vaccines work by training the immune system to recognize specific cancer-related antigens, substances found on cancer cells that can trigger an immune response. By introducing these antigens into the body, cancer vaccines aim to activate the immune system's natural defense mechanisms against cancer. There are two main types of cancer vaccines, namely preventive (prophylactic) and therapeutic vaccines. Preventive cancer vaccines are used to prevent certain types of cancer caused by infectious agents, such as human papillomavirus (HPV) or hepatitis B virus (HBV). These vaccines stimulate the immune system to produce an immune response against the infectious agent, reducing the risk of developing associated cancers. Therapeutic cancer vaccines, on the other hand, are designed to treat existing cancers. They work by boosting the immune response against cancer cells, either by introducing cancer-specific antigens or by enhancing the immune system's recognition of these antigens. These vaccines can be personalized, targeting specific antigens present in an individual patient's tumor cells.

The rising prevalence of cancer worldwide is a significant driver for the cancer vaccines market. With cancer being a leading cause of mortality, there is a growing demand for effective preventive and therapeutic interventions. Additionally, immunotherapy, including cancer vaccines, has emerged as a promising treatment approach in oncology. The development of novel immunotherapeutic strategies and the success of existing immunotherapies have propelled the demand for cancer vaccines. Other than this, there is a rising awareness among the general population about the importance of cancer prevention and early detection. Increased education campaigns, screening programs, and public awareness initiatives have resulted in a greater demand for preventive measures, including cancer vaccines. Besides this, the market has witnessed collaborations between pharmaceutical companies, research institutes, and academic institutions. These partnerships facilitate the exchange of knowledge, resources, and expertise, leading to accelerated development and commercialization of cancer vaccines. In line with this, the growing healthcare expenditure, particularly in emerging economies, has boosted the accessibility and affordability of cancer vaccines. Rising disposable incomes, improving healthcare infrastructure, and expanding insurance coverage are contributing to market growth. Moreover, governments across the globe are actively investing in cancer research and development, including vaccines, which is creating a positive market outlook.

Cancer Vaccines Market Trends/Drivers:

Advancements in immunotherapy

Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to target and destroy cancer cells. The success of immunotherapeutic approaches, including checkpoint inhibitors and adoptive cell therapies, has created a strong foundation for the development and adoption of cancer vaccines. The ability of cancer vaccines to stimulate a specific immune response against tumor antigens further complements existing immunotherapy strategies. This synergy has fueled the demand for cancer vaccines as an integral part of combination therapies, leading to their market growth.

Government initiatives and funding

Governments worldwide have recognized the urgent need to address the growing burden of cancer. As a result, they are actively investing in cancer research, development, and healthcare infrastructure. Governments provide financial support, grants, and incentives to companies engaged in cancer vaccine research and development. Additionally, regulatory agencies are working closely with vaccine developers to streamline approval processes and facilitate market access. These supportive policies and funding initiatives have significantly contributed to the growth of the market, enabling companies to invest in research, clinical trials, and manufacturing capabilities.

Growing awareness and education

Increased awareness among the general population about cancer prevention and early detection has had a profound impact on the demand for cancer vaccines. Public health campaigns, educational programs, and initiatives by advocacy groups have emphasized the importance of vaccinations as a preventive measure against certain cancers. The success of preventive vaccines for infections linked to cancer, such as HPV and HBV vaccines, has further reinforced the significance of cancer vaccines. As people become more knowledgeable about the benefits of cancer prevention and immunization, the demand for cancer vaccines is expected to increase, thus driving market growth.

Cancer Vaccines Industry Segmentation:

This report provides an analysis of the key trends in each segment of the global cancer vaccines market report, along with forecasts at the global, regional and country levels from 2026-2034. The report categorizes the market based on type, technology, indication and end user.

Breakup by Type:

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

Preventive cancer vaccines dominate the market

Preventive cancer vaccines have demonstrated significant success in reducing the incidence of specific cancers associated with infectious agents. Vaccines, such as the human papillomavirus (HPV) and hepatitis B virus (HBV), have proven effective in preventing cervical, anal, and certain types of liver cancer, respectively. The efficacy and safety of these vaccines have led to their widespread acceptance. Additionally, these vaccines offer a proactive approach to cancer prevention. They target specific infectious agents known to contribute to the development of certain cancers, thereby providing a direct means of prevention. This approach is especially appealing as it focuses on reducing the risk of developing cancer in the first place, rather than solely relying on early detection or treatment interventions. As public awareness of the benefits of preventive measures increases, individuals and healthcare providers are embracing the use of preventive cancer vaccines, thus contributing to the segment's market dominance. Other than this, preventive cancer vaccines align with global efforts to reduce the burden of cancer. Moreover, governments and healthcare organizations across the world have recognized the value of prevention in combating cancer and have implemented vaccination programs as part of their public health initiatives. These programs target specific populations, such as adolescents for HPV vaccination, to maximize the preventive impact. The extensive implementation of national immunization programs and the inclusion of preventive cancer vaccines in routine vaccination schedules further drive the market segment.

Breakup by Technology:

  • Dendritic Cells Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Antigen/Adjuvant Cancer Vaccines
  • Viral Vector and DNA Cancer Vaccines
  • Whole-cell Cancer Vaccines

Recombinant cancer vaccines hold the largest share in the market

Recombinant technology allows for precise and controlled production of cancer vaccines. These vaccines are developed by inserting specific genes or DNA sequences encoding tumor antigens into a vector such as a virus or bacteria. This genetic engineering technique enables researchers to create vaccines that express tumor-specific antigens, effectively targeting cancer cells while minimizing potential side effects. The ability to tailor the vaccine's composition and antigen profile to match the specific characteristics of a patient's tumor makes recombinant cancer vaccines highly customizable and attractive in personalized medicine approaches. Additionally, recombinant vaccines have demonstrated favorable safety and efficacy profiles. The use of recombinant technology allows for the production of vaccines without using live or attenuated pathogens, reducing the risk of adverse events. Additionally, recombinant vaccines can induce a robust immune response by presenting tumor-specific antigens to the immune system in a controlled manner. This targeted immune response enhances the vaccine's efficacy in recognizing and attacking cancer cells. Other than this, this technology offers scalability and cost-effectiveness in vaccine production. The use of recombinant techniques allows for efficient large-scale production of vaccines, thus meeting the demand for widespread vaccination programs.

Breakup by Indication:

  • Cervical Cancer
  • Prostate Cancer
  • Others

Cervical cancer is primarily caused by persistent infection with high-risk types of human papillomavirus (HPV). Vaccines targeting HPV have been successful in preventing cervical cancer. The market for cervical cancer vaccines is driven by the increasing awareness about the role of HPV in cervical cancer development, along with the implementation of national vaccination programs. Vaccines, such as Gardasil and Cervarix, have been developed specifically to prevent HPV infection and subsequent development of cervical cancer. These vaccines have shown remarkable efficacy in preventing HPV infections and reducing the incidence of cervical precancerous lesions. The market segment for cervical cancer vaccines is expected to grow as vaccination rates improve and more countries include HPV vaccination in their immunization programs.

Prostate cancer is the most common cancer among men, and the demand for effective treatment options is high. Vaccines targeting prostate cancer work by stimulating the immune system to recognize and attack prostate cancer cells. Sipuleucel-T (Provenge) is an example of an FDA-approved therapeutic vaccine for advanced prostate cancer. It is designed to boost the patient's immune response against prostate cancer cells. The market for prostate cancer vaccines is driven by the need for innovative treatment options that can improve overall survival and quality of life for patients. Additionally, the rising prevalence of prostate cancer, especially in aging population, contributes to the market growth. Moreover, ongoing research and clinical trials developing new prostate cancer vaccines, is further enhancing the potential of this market segment.

Breakup by End User:

  • Pediatrics
  • Adults

Pediatric patients, including infants, children, and adolescents, represent a crucial target population for cancer vaccines. Vaccination in pediatrics aims to prevent cancers associated with infectious agents, such as cervical cancer caused by HPV or liver cancer caused by HBV. Vaccinating children and adolescents against these infections can provide long-term protection and reduce the risk of developing associated cancers in adulthood. Government immunization programs and initiatives aimed at promoting pediatric vaccination have been instrumental in driving the market growth. Other than this, the demand for pediatric cancer vaccines is expected to increase with the increasing awareness about the benefits of early prevention and vaccination.

While pediatric vaccination focuses on preventing cancers in early stages of life, adult vaccination targets both preventive and therapeutic purposes. In terms of prevention, adult cancer vaccines primarily aim to protect against infectious agents that contribute to certain cancers, such as HPV-associated cancers, HBV-related liver cancer, and human immunodeficiency virus (HIV)-associated cancers. Additionally, therapeutic vaccines targeting specific antigens expressed by cancer cells are being developed for adult patients. These therapeutic vaccines are designed to stimulate the immune system and enhance the body's ability to recognize and attack cancer cells. The market for adult cancer vaccines is driven by the growing emphasis on preventive healthcare, increasing awareness regarding vaccination benefits in adults, and advancements in therapeutic vaccine research and development.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America has a well-developed healthcare infrastructure and advanced research capabilities. The region is home to numerous leading pharmaceutical and biotechnology companies, academic institutions, and research centers specializing in cancer research. This robust ecosystem fosters innovation, enabling the development and commercialization of cutting-edge cancer vaccines. The presence of well-established regulatory frameworks and stringent quality standards further supports the growth of the market in North America. Additionally, there is a high prevalence of cancer in this region, which is accelerating the adoption of effective treatment options, including cancer vaccines. The region experiences a significant burden of various cancers, such as lung, breast, prostate, and colorectal cancers. This increased incidence of cancer creates a substantial market opportunity for cancer vaccines as patients and healthcare providers seek novel therapies for prevention, treatment, and improved patient outcomes. Other than this, North America has a strong emphasis on preventive healthcare and vaccination programs. The region's healthcare systems prioritize disease prevention and public health initiatives, including immunization campaigns. Moreover, vaccination against infectious agents associated with certain cancers, such as HPV and HBV, is actively promoted, leading to a higher uptake of preventive cancer vaccines.

Competitive Landscape:

Key players are actively investing in research and development to advance the development of cancer vaccines. They are focused on identifying novel tumor antigens, optimizing vaccine formulations, and exploring innovative delivery systems. Healthcare companies are conducting extensive preclinical and clinical trials to demonstrate the safety, efficacy, and potential of their cancer vaccine candidates. These trials involve collaboration with healthcare institutions and involve a large patient population. By supervising rigorous clinical trials, they are gathering valuable data on the performance of their vaccines, demonstrating their efficacy, and paving the way for regulatory approvals and market entry. Other than this, key players are actively working on expanding market access for cancer vaccines. They are involved in obtaining regulatory approvals in various countries, ensuring manufacturing scalability, and establishing distribution networks. Companies are also focused on educating healthcare providers, patients, and the general public about the benefits of cancer vaccines. Marketing and promotional activities are carried out to create awareness, enhance adoption rates, and drive market growth. Besides this, they continue to invest in their product pipelines and drive innovation in the market by constantly exploring new vaccine candidates, improving existing formulations, and discovering novel approaches to enhance immune responses.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Anixa Biosciences Inc.
  • Dendreon Pharmaceuticals LLC
  • Dynavax Technologies Corporation
  • GSK plc
  • Merck & Co. Inc.
  • Moderna Inc.
  • OSE Immunotherapeutics
  • Providence Therapeutics
  • Sanofi S.A.
  • UbiVac Inc.
  • Vaccitech PLC

Key Questions Answered in This Report

1. How big is the global cancer vaccines market?

2. What is the expected growth rate of the global cancer vaccines market during 2026-2034?

3. What are the key factors driving the global cancer vaccines market?

4. What has been the impact of COVID-19 on the global cancer vaccines market?

5. What is the breakup of the global cancer vaccines market based on the type?

6. What is the breakup of the global cancer vaccines market based on the technology?

7. What are the key regions in the global cancer vaccines market?

8. Who are the key players/companies in the global cancer vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Preventive Cancer Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Therapeutic Cancer Vaccines
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Technology

  • 7.1 Dendritic Cells Cancer Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Recombinant Cancer Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Antigen/Adjuvant Cancer Vaccines
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Viral Vector and DNA Cancer Vaccines
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Whole-cell Cancer Vaccines
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cervical Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Prostate Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pediatrics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Adults
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Anixa Biosciences Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Dendreon Pharmaceuticals LLC
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Dynavax Technologies Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 GSK plc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Merck & Co. Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Moderna Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 OSE Immunotherapeutics
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Providence Therapeutics
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 UbiVac Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Vaccitech plc
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials

List of Figures

  • Figure 1: Global: Cancer Vaccines Market: Sales Value (in Billion USD), 2020-2025
  • Figure 2: Global: Cancer Vaccines Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 3: Global: Cancer Vaccines Market: Breakup by Type (in %), 2025
  • Figure 4: Global: Cancer Vaccines Market: Breakup by Technology (in %), 2025
  • Figure 5: Global: Cancer Vaccines Market: Breakup by Indication (in %), 2025
  • Figure 6: Global: Cancer Vaccines Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Cancer Vaccines Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Cancer Vaccines (Preventive Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Cancer Vaccines (Therapeutic Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Cancer Vaccines (Dendritic Cells Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Cancer Vaccines (Recombinant Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Cancer Vaccines (Antigen/Adjuvant Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Cancer Vaccines (Viral Vector and DNA Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Cancer Vaccines (Whole-cell Cancer Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Cancer Vaccines (Cervical Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Cancer Vaccines (Cervical Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Cancer Vaccines (Prostate Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Cancer Vaccines (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Cancer Vaccines (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Cancer Vaccines (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Cancer Vaccines (Pediatrics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Cancer Vaccines (Pediatrics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Cancer Vaccines (Adults) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Cancer Vaccines (Adults) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Cancer Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Cancer Vaccines Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Cancer Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Cancer Vaccines Industry: SWOT Analysis
  • Figure 82: Global: Cancer Vaccines Industry: Value Chain Analysis
  • Figure 83: Global: Cancer Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Vaccines Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Cancer Vaccines Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Cancer Vaccines Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 4: Global: Cancer Vaccines Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 5: Global: Cancer Vaccines Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Cancer Vaccines Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Cancer Vaccines Market: Competitive Structure
  • Table 8: Global: Cancer Vaccines Market: Key Players